NCT03894150View on ClinicalTrials.gov

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

July 1, 2020

Study Completion Date

March 12, 2024

Conditions
Refractory or Recurrent CD30+ Hematologic Malignancies
Interventions
DRUG

F0002-ADC

Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

450008

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY

NCT03894150 - A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. | Biotech Hunter | Biotech Hunter